Avid Bioservices Inc (CDMO)

[biopharm]

With Opdivo trial failures and JUNO (MSK collaborator) trial failures and the ever increasing groups that realize that responders are LOW for IO treatment .( Opdivo ...Keytruda...) and the many others falling behind n this race...all mean that Dr Wolchok should be excited about Bavituximab or any other PS Targeting drug

The headlines are there waiting for the one who is allowed to advance PS Targeting

So we eventually all just found out this past month, that Dr. Wolchok validated PS Targeting. Now,other Immunotherapies are having some tough times due to safety and JUNO has already gone through trials with MSK and due to patient deaths, those trials halted.

So here we go again.... JUNO in trouble again and now do we see why the validation by Dr. Jedd Wolchok means for Peregrine? It means other pipelines that do not want to fail will also seek the advice from some like Dr. Wolchok.

How about using something else JUNO for a primer, like a primer to reach that optimal immune response and give all patients a fighting chance to battle cancer with their own immune system and survive.

PS Targeting is required.

-------------------------------------------------------

Cancer immunotherapy trial stopped again after 2 more deaths

Nov 23, 2016 - 8:57pm

(CNN)After more patient deaths, Juno Therapeutics announced Wednesday that it is voluntarily putting its "ROCKET" trial on hold for the second time this year. The patients enrolled in this Phase II trial are adults with relapsed or refractory B cell acute lymphoblastic leukemia, according to the biopharmaceutical company's website.
"We took this action after two additional patients in this trial experienced cerebral edema earlier this week," Juno CEO Hans Bishop said on a conference call this morning. One patient died Tuesday, and another died earlier Wednesday.

Acute lymphoblastic leukemia is a type of blood cancer that can spread quickly through the body and, if left untreated, can be fatal within months. Cerebral edema is brain swelling caused by excess fluid inside the skull.

In July, the trial was put on a clinical hold at the direction of the Food and Drug Administration. At that time, the company revealed three patient deaths, also the result of cerebral edema. [color=red]According to Bishop, investigators pinpointed the likely culprit as the addition of fludarabine to the pre-conditioning regimen. Fludarabine is a chemotherapy drug used here as a one-time primer for treatment, used in an effort to increase the effectiveness of the experimental therapy. [/color]

In this particular course of treatment, pre-conditioning consists of a heavy dose of chemotherapy to kill off existing cancer cells in order to give the new cancer-killing T-cells room to grow. It's like hitting a reset button to restart the immune system. But an unforeseen interaction between fludarabine and genetically modified JCAR015 cells proved to be lethal.
After petitioning the FDA, Juno was permitted to continue the trial without the use of fludarabine. In August, the trial resumed, and 12 patients have been treated since, said Juno Chief Medical Officer Mark Gilbert on Wednesday. This includes the two patients who died this week after being treated last week.
The FDA monitors all US drug trials and says fatal adverse events are "extremely rare."

Immunotherapy has been heralded as the new frontier in the war on cancer. It works by harnessing the body's immune system to fight cancer from within. But many of these cutting-edge treatments are still in the experimentation phase.
A Phase II clinical trial is designed to test the effectiveness of a new drug or treatment. It typically follows a Phase I trial, which evaluates safety and side effects. Before a new drug or treatment goes to market, it must also pass through a Phase III trial, as outlined by the National Institutes of Health.
"Going forward, all options remain on the table for JCAR015," Bishop said Wednesday. "The options include, among others: moving forward with JCAR015 in the current study under a modified protocol, beginning a new study or terminating the program."
Juno's other ongoing trials, including JCAR017 cells, are not affected, according to the company.

"Any decision on how to move forward will of course need to be made, taking into account feedback from the FDA and our (Data and Safety Monitoring Board), as well as the treating physicians in the trial," Bishop said. He added that the patients in this trial often have no other options.
Bishop said the company plans to provide a more thorough update in the next few weeks.

http://www.cnn.com/2016/11/23/health/juno-stops-cancer-immunotherapy-trial-again/